Sep 07, 2022 / 05:50PM GMT
Andrew Simon Baum - Citigroup Inc., Research Division - Global Head of Healthcare Research and MD
Delighted to introduce our session. We have 2 key speakers from GSK. We have the President of Vaccines and Global Health Roger Connor and then secondly, we have Phil Dormitzer, who recently joined from Pfizer, who is, I'm going to say, head of R&D and Vaccines. correct? Got it. Okay. I have to make sure I get the terminology correct.
So look, I won't draw on the share price impact from the ongoing focus on nitrosamines and the concern over liability. But putting that aside, Vaccines has been an area which I know the company is feeling increasingly upbeat on. We're going to talk about the RSV update. We're going to talk about Shingrix, and then I want to spend some time talking about some of the next-generation vaccines that you have in your pipe.
Questions and Answers:
Andrew Simon Baum - Citigroup Inc., Research Division - Global Head of Healthcare Research and MDSo maybe to kick off on Shingrix, could you update us as to the levels of
Trustpilot
